Search

Syndax Pharmaceuticals Inc

Atvērts

SektorsVeselības aprūpe

16.96 -1.74

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

17

Max

17.69

Galvenie mērījumi

By Trading Economics

Ienākumi

-6.7M

-49M

Pārdošana

7.9M

73M

EPS

-0.55

Peļņas marža

-67.817

Darbinieki

298

EBITDA

-5.9M

-37M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+114.93% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 2. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-125M

1.6B

Iepriekšējā atvēršanas cena

18.7

Iepriekšējā slēgšanas cena

16.96

Ziņu noskaņojums

By Acuity

77%

23%

300 / 340 Rangs Healthcare

Syndax Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. okt. 20:07 UTC

Syndax Pharmaceuticals Inc shares fell sharply, hitting a low of over 5% earlier, and remain below the 20-day moving average.

2026. g. 2. okt. 19:15 UTC

Syndax Pharmaceuticals Inc shares fell sharply, facing significant downward pressure and trading notably below its 20-day moving average amid broader biotechnology sector weakness.

2026. g. 1. okt. 20:07 UTC

Social Media

Shares of Syndax Pharmaceuticals fell despite positive analyst ratings from H.C. Wainwright and Jefferies, remaining below the 20-day moving average.

2026. g. 30. sept. 20:07 UTC

Syndax Pharmaceuticals Inc is experiencing gains in Wednesday's trading session, rebounding significantly after an early dip and achieving a notable cumulative return since Tuesday.

2026. g. 29. sept. 23:30 UTC

Syndax Pharmaceuticals Inc is rising in after-market trading, advancing from a low point post-market close and currently near the midpoint of its one-month trading range.

2026. g. 28. sept. 19:16 UTC

News

Syndax Pharmaceuticals Inc. shares fell, remaining below the 20-day moving average despite being rated a "Strong Buy" following FDA approval for Revuforj.

2026. g. 25. sept. 19:46 UTC

News
Social Media

Syndax Pharmaceuticals reaffirms over $2 billion in U.S. peak sales for Revuforj after SAVE trial results show an 88% overall response rate, driving shares higher.

2026. g. 24. sept. 20:12 UTC

Syndax Pharmaceuticals Inc is trading higher in after-market hours, maintaining a steady position since Thursday's close, despite being below its 20-day moving average.

2026. g. 23. sept. 20:07 UTC

Syndax Pharmaceuticals Inc shares fell sharply, reaching their lowest point around midday and remaining below the 20-day moving average after a significant decline from Tuesday's close.

2026. g. 22. sept. 19:45 UTC

Syndax Pharmaceuticals Inc is trading modestly higher, though the price remains below its 20-day moving average and near the lower end of its one-month range.

2026. g. 21. sept. 21:11 UTC

Syndax Pharmaceuticals Inc is advancing in after-market trading, reflecting notable upward movement since Monday's close, despite remaining below its 20-day moving average.

2026. g. 17. sept. 20:07 UTC

Syndax Pharmaceuticals Inc is trading higher, having seen a steady increase, despite being below its 20-day moving average and near the lower end of its one-month range.

2026. g. 16. sept. 20:06 UTC

Macro Event

Syndax Pharmaceuticals Inc shares fell sharply, driven by heightened volatility in the healthcare sector following the Federal Reserve's recent 25 basis point interest rate hike.

2026. g. 15. sept. 20:07 UTC

Syndax Pharmaceuticals Inc shares are lower amid a broader market decline following a sharp drop in the NY Empire State Manufacturing Index for September.

2026. g. 11. sept. 19:36 UTC

News

Syndax Pharmaceuticals is lower today, continuing a downward trend amid heightened market volatility following the August Consumer Price Index release.

2026. g. 10. sept. 20:03 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

2026. g. 8. sept. 20:07 UTC

News

Syndax Pharmaceuticals is lower today amid broader market weakness and speculation about a Federal Reserve interest rate hike following strong labor data.

2026. g. 2. sept. 20:08 UTC

Syndax Pharmaceuticals Inc shares are higher today, despite earlier pulling back from a session high amid broader market volatility and slower job growth indicators.

2026. g. 1. sept. 20:09 UTC

News

Syndax Pharmaceuticals shares are higher as the company announces participation in two investor conferences to boost visibility for its cancer therapies.

2026. g. 25. aug. 19:26 UTC

Syndax Pharmaceuticals Inc shares are higher today, maintaining gains since Monday. The stock remains above the 20-day moving average amid declining yields.

2026. g. 24. aug. 19:51 UTC

Syndax Pharmaceuticals Inc is trading lower, breaking a trend of higher closes. Broader market sentiment is impacted by concerns over U.S.-Iran relations and oil supply disruptions.

2026. g. 21. aug. 19:21 UTC

Syndax Pharmaceuticals shares are lower today, breaking a trend of higher closes since Thursday. The broader market faces volatility amid rising crude oil prices.

2026. g. 20. aug. 20:02 UTC

Correlated Moves

Syndax trades lower amid decline in SPDR S&P Biotech ETF.

2026. g. 19. aug. 19:27 UTC

Correlated Moves

SNDX higher today, supported by strong biotechnology sector performance.

2026. g. 18. aug. 19:56 UTC

Syndax Pharmaceuticals is trading higher today, despite pulling back from earlier session gains. The stock remains positioned near the lower end of its one-month range.

2026. g. 17. aug. 19:36 UTC

Correlated Moves

Shares higher today as iShares Biotechnology ETF also gains.

2026. g. 14. aug. 19:26 UTC

Syndax Pharmaceuticals Inc shares are trading higher during Friday's session, reflecting positive market sentiment despite broader concerns over a decline in U.S. retail sales.

2026. g. 12. aug. 19:31 UTC

Syndax Pharmaceuticals shares are lower, reversing a recent trend of gains. No specific news was identified to explain the decline.

2026. g. 11. aug. 19:26 UTC

News

SNDX trades lower after JPMorgan cuts price target to $40.00.

2026. g. 10. aug. 19:36 UTC

Syndax Pharmaceuticals shares are lower amid broader market volatility and rising oil prices due to geopolitical tensions in the Strait of Hormuz.

Salīdzinājums

Cenas izmaiņa

Syndax Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

114.93% augšup

Prognoze 12 mēnešiem

Vidējais 37.333 USD  114.93%

Augstākais 57 USD

Zemākais 26 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Syndax Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

10

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

300 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.